Test Name
NRAS EXON 1 AND 2 MUTATION
Aliases
-
Abbreviations
-
Test Classification
INDIVIDUAL
Department
MOLECULAR PATHOLOGY
Sub Department
ONCOLOGY
TAT Category
ELAPSED (CONTINUOUS) TIME
Estimated TAT
10
TAT Units
DAYS
Test Requirements
Tumor containing FFPE block (>10% of tumor). Tumor-containing tissue was fixed in 10% neutral buffered formalin for a duration of 6 to 72 hours. If tissue is provided, then tissue processing and FFPE block-making charges will be applicable. Clinical history and histopathology report are required.
Clinical Utility
NRAS mutations (exons 1 and 2, codons 12, 13, and 18) are clinically relevant across several cancers/ malignancies.
1. In colorectal cancer, mutation status must be confirmed before initiating anti-EGFR therapy (e.g. cetuximab, panitumumab). Mutations predict non-response/ resistance to anti-EGFR therapies.
2. In melanoma, NRAS mutations (~15–20% of cases) help guide MEK inhibitor therapy eligibility.
3. In haematological malignancies (AML, CMML), they carry prognostic value.
Testing therefore drives targeted therapy decision-making, prevents exposure to ineffective treatments, and supports prognostic stratification.
Last Review
26th Feb 2026